Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Automated Brain Tumor biopsy prediction using single-labeling cDNA Microarrays-based gene expression profiling

  • Castells, Xavier
  • Navarro, Alfredo
  • Acebes, Juan José
  • Godino, Óscar
  • Boluda, Susana
  • Barceló, Anna
  • Robles, Montserrat
  • Ariño, Joaquín
  • Arús, Carles
  • Garcia-Gomez, Juan M
[EN] Aims: Gene signatures obtained from microarray experiments may be of use to improve the prediction of brain tumor diagnosis. Nevertheless, automated and objective prediction with accuracy comparable to or better than the gold standard should be convincingly demonstrated for possible clinician uptake of the new methodology. Herewith, we demonstrate that primary brain tumor types can be discriminated using microarray data in an automated and objective way. Methods: Postsurgical biopsies from 35 patients [17 glioblastoma multiforme (Gbm) and 18 meningothelial meningioma (Mm)] were stored in liquid nitrogen, total RNA was extracted, and cDNA was labeled with Cy3 fluorochrome and hybridized onto a cDNA-based microarray containing 11,500 cDNA clones representing 9300 loci. Scanned data were preprocessed, normalized, and used for predictor development. The predictive functions were fitted to a subset of samples and their performance evaluated with an independent subset. Expression results were validated by means of real time-polymerase chain reaction. Results: Some gene expression-based predictors achieved 100% accuracy both in training resampling validation and independent testing. One of them, composed of GFAP, PTPRZ1, GPM6B and PRELP, produced a 100% prediction accuracy for both training and independent test datasets. Furthermore, the gene signatures obtained, increased cell detoxification, motility and intracellular transport in Gbm, and increased cell adhesion and cytochrome-family genes in Mm, agree well with the expected biologic and pathologic characteristics of the studied tumors. Conclusions: The ability of gene signatures to automate prediction of brain tumors through a fully objective approach has been demonstrated. A comparison of gene expression profiles between Gbm and Mm may provide additional clues about patterns associated with each tumor type., Supported in part by grants from the European Commission (FP6-2002-LIFESCIHEALTH 503094 and IST-2004-27214), the research project MEDIVO2 (MEC, SAF2005-03650), and the Programa de Apoyo a la lnvestigacion y Desarrollo (PAID-00-06 UPV)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy

  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Luts, Jan
  • Julia-Sape, Margarida
  • Krooshof, Patrick
  • Tortajada Velert, Salvador
  • Vicente Robledo, Javier
  • Melssen, Willem
  • Olier, Ivan
  • Postma, Geert
  • Monleon, Daniel
  • Moreno-Torres, Angel
  • Pujol, Jesus
  • Candiota, Ana-Paula
  • Suykens, Johan
  • Buydens, Lutgarde
  • Celda, Bernardo
  • Van Huffel, Sabine
  • Arus, Carles
  • Robles Viejo, Montserrat
[EN] Automatic brain tumor classification by MRS has been under development for more than a decade. Nonetheless, to our knowledge, there are no published evaluations of predictive models with unseen cases that are subsequently acquired in different centers. The multicenter eTUMOUR project (2004-2009), which builds upon previous expertise from the INTERPRET project (2000-2002) has allowed such an evaluation to take place. A total of 253 pairwise classifiers for glioblastoma, meningioma, metastasis, and low-grade glial diagnosis were inferred based on 211 SV short TE INTERPRET MR spectra obtained at 1.5 T (PRESS or STEAM, 20-32 ms) and automatically pre-processed. Afterwards, the classifiers were tested with 97 spectra, which were subsequently compiled during eTUMOUR. In our results based on subsequently acquired spectra, accuracies of around 90% were achieved for most of the pairwise discrimination problems. The exception was for the glioblastoma versus metastasis discrimination, which was below 78%. A more clear definition of metastases may be obtained by other approaches, such as MRSI + MRI. The prediction of the tumor type of in-vivo MRS is possible using classifiers developed from previously acquired data, in different hospitals with different instrumentation under the same acquisition protocols. This methodology may find application for assisting in the diagnosis of new brain tumor cases and for the quality control of multicenter MRS databases., We would like to thank the INTERPRET and eTUMOUR partners for providing data, particularly, Carles Majos (IDI-Bellvitge), John Griffiths and Franklyn Howe (SGUL), Arend Heerschap (RU), Witold Gajewicz (MUL), Jorge Calvar (FLENI), and Antoni Capdevila (H. de Sant Joan de Deu). This work was partially funded by the European Commission: eTUMOUR (contract no. FP62002-LIFESCIHEALTH 503094), the HEALTHAGENTS EC project (HEALTHAGENTS) (contract no. FP6-2005-IST 027213), BIOPATTERN (contract no. FP6-2002-IST 508803). The authors appreciate the suggestions from the reviewers that have improved the discussion presented in this work. We also thank the following for their contributions: Programa de Apoyo a la Investigacion y Desarrollo, PAID-00-06 UPV; Research Council KUL: GOA-AMBioRICS, Centers-of-excellence optimisation; Belgian Federal Government: DWTC, IUAPV P6/04 (DYSCO 2007-2011); the following participants acknowledge the following: JVR acknowledges to Programa Torres Quevedo from Ministerio de Educacion y Ciencia, co-founded by the European Social Fund (PTQ05-02-03386). JL is a PhD student supported by an IWT grant. DM is supported by the Ministerio de Educacion y Ciencia del Gobierno de Espa a for a Ramon y Cajal 2006 Contract. BC and CA gratefully acknowledge the Ministerio de Educacion y Ciencia del Gobierno de Espa a (BC: SAF2004-06297 and SAF2007-6547; CA: SAF2005-03650). CIBER-BBN is an initiative of the "Instituto de Salud Carlos III" (ISCIII), Spain
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of robust discriminant equations for assessing subtypes of glioblastoma biopsies

  • Castells Domingo, Xavier
  • Acebes Martín, Juan José
  • Majos, Carles|||0000-0003-0468-5150
  • Boluda, Susana
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Ariño Carmona, Joaquín|||0000-0002-6774-2987
  • Barceló, Antonia
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
In the preceding decade, various studies on glioblastoma (Gb) demonstrated that signatures obtained from gene expression microarrays correlate better with survival than with histopathological classification. However, there is not a universal consensus formula to predict patient survival. We developed a gene signature using the expression profile of 47 Gbs through an unsupervised procedure and two groups were obtained. Subsequent to a training procedure through leave-one-out cross-validation, we fitted a discriminant (linear discriminant analysis (LDA)) equation using the four most discriminant probesets. This was repeated for two other published signatures and the performance of LDA equations was evaluated on an independent test set, which contained status of IDH1 mutation, EGFR amplification, MGMT methylation and gene VEGF expression, among other clinical and molecular information. The unsupervised local signature was composed of 69 probesets and clearly defined two Gb groups, which would agree with primary and secondary Gbs. This hypothesis was confirmed by predicting cases from the independent data set using the equations developed by us. The high survival group predicted by equations based on our local and one of the published signatures contained a significantly higher percentage of cases displaying IDH1 mutation and non-amplification of EGFR. In contrast, only the equation based on the published signature showed in the poor survival group a significant high percentage of cases displaying a hypothesised methylation of MGMT gene promoter and overexpression of gene VEGF. We have produced a robust equation to confidently discriminate Gb subtypes based in the normalised expression level of only four genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS

  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Majos, Carles|||0000-0003-0468-5150
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Cabañas Egaña, Miquel|||0000-0003-0104-0197
  • Acebes Martín, Juan José
  • Moreno Torres, Angel
  • Griffiths, J. R.
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
MRI and MRS are established methodologies for evaluating intracranial lesions. One MR spectral feature suggested for in vivo grading of astrocytic tumours is the apparent myo-Inositol (mI) intensity (ca 3.55ppm) at short echo times, although glycine (gly) may also contribute in vivo to this resonance. The purpose of this study was to quantitatively evaluate the mI + gly contribution to the recorded spectral pattern in vivo and correlate it with in vitro data obtained from perchloric acid extraction of tumour biopsies. Patient spectra (n = 95) at 1.5T at short (20-31 ms) and long (135-136 ms) echo times were obtained from the INTERPRET MRS database (http://gabrmn.uab.es/interpretvalidateddb/). Phantom spectra were acquired with a comparable protocol. Spectra were automatically processed and the ratios of the (mI + gly) to Cr peak heights ((mI + gly)/Cr) calculated. Perchloric acid extracts of brain tumour biopsies were analysed by high-resolution NMR at 9.4T. The ratio (mI + gly)/Cr decreased significantly with astrocytic grade in vivo between low-grade astrocytoma (A2) and glioblastoma multiforme (GBM). In vitro results displayed a somewhat different tendency, with anaplastic astrocytomas having significantly higher (mI + gly)/Cr than A2 and GBM. The discrepancy between in vivo and in vitro data suggests that the NMR visibility of glycine in glial brain tumours is restricted in vivo.